Prophylaxis and treatment of iron deficiency anemia in multiple pregnancies

Authors: T.G. Romanenko, O.V. Morozova, O.M. Sulimenko


The objective: to reduce the frequency and severity of iron deficiency anemia (IDA) in multiple pregnancies by optimizing its prevention, treatment and proving the effectiveness and safety of the therapy.

Materials and methods

90 pregnant women were under observation. The control group (CG) consisted of 30 pregnant women with one fetus, group I – 30 women with multiple pregnancies who did not use the recommended therapy, group II – 30 women with multiple pregnancies, conducted according to our proposed method.

The effectiveness of therapy was evaluated weekly by subjective evaluation of improvement and according to laboratory parameters of peripheral blood.

General clinical methods included clinical, general blood analysis and determination of serum iron, quantitative determination of the concentration of sulfhydryl groups and lipoproteins in erythrocyte elements of peripheral blood, studied the surface architecture of erythrocyte membranes.

Results

There was a significant reduction in the frequency and severity of IDA in pregnant women of group II in 1.6 times.Diagnosed with a significant increase in the number of discocytes (group I 67.34±0.81; group II 84.53±1.04; p<0.05), a decrease in the number of ellipses (group I 0.99±0.05; group II 0,60±0.05; p<0.05); flat disks (group I 0.87±0.07; group II 0.56±0.03; p<0.05); dome-shaped (I group 2,41±0,14; ІІ group 1,82±0,11; р<0,05) and spherical erythrocytes (І group 4,11±0,12; ІІ group 2,44±0, 13; p<0.05). Significant decrease in the number of transitional forms (group I 3.41±0.31%; group II 2.53±0.21; p<0.05); pre hemolytic (I group 2,41±0,14%; ІІ group 1,44±0,11%; р<0,05) and degenerative forms (І group 1,18±0,14%; ІІ group 0,52 ±0.03; p<0.05), as well as the ratio of the inner and outer diameters of erythrocytes (group I 66.71±0.91; group II 45.81±0.63; p<0.05). There was a significant increase in the ratio of sulfhydryl groups and lipoproteins in erythrocyte membranes.

Conclusions

The complex composition of the drug Fersinol and Fersinol-Z, taking into account the effective antianemic action, can be considered optimal for the prevention and treatment of iron deficiency in multiple pregnancies and recommended for use in practical health care.

Key words: multiple pregnancy, iron deficiency anemia, prevention, treatment, Fersinol ampoules, Fersinol-Z (Fersinol-Z) capsules.

Published in the magazine “Women’s Health” №4 (150) `2020

ARTICLES FROM CATEGORY
Support of educational events. Participation of World Medicine in the First Congress of Optometrists of Ukraine.
Cetirizine is an effective and safe antihistamine (literature review, results of clinical researches)
All-Ukrainian Scientific and Practical Conference “Aspects of Internal Medicine in Wartime 2024"

PROVE YOU ARE A MEDICAL PROFESSIONAL

Attention: This section is intended for healthcare professionals only. If you are not a medical professional, you can return to the main page by clicking the “No” option

CARD-NOTIFICATION OF AN ADVERSE DRUG REACTION AND/OR LACK OF EFFICACY OF THE MEDICINE

INFORMATION ABOUT THE PATIENT

SUSPECTED AR/LE

Suspected AR (describe each clinical manifestation of the AR with dates and times of onset and end and outcome)/Indication of the LE

INFORMATION ABOUT SUSPECTED MEDICINES

INFORMATION ABOUT RELATED MEDICINES

(with the exception of drugs used to correct the effects of AR/LE)
(concomitant diagnoses, laboratory and instrumental studies, allergy history, pregnancy with gestational age, method of conception, pregnancy outcome (if the pregnancy ended, the date of delivery, type of delivery, etc.)

Information about the messenger

INFORMATION ABOUT THE MEDICAL/PHARMACY SPECIALIST

(if not the notifier)

MESSAGE CARD for the patient

to provide the patient and/or his/her representative with information on adverse drug reactions and/or lack of efficacy of the drug

INFORMATION ABOUT THE PATIENT

Information about the suspected medicine

Information on the prescription of the suspected medicinal product

Information about the messenger

Information about the physician, healthcare facility and place of residence of the patient who had an adverse medicine reaction and/or lack of efficacy of the medicine

розробка сайту Estetic web design